Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial
Anne Sofie Ledgaard Loftagera Incentive Denmark Aps, Holte, Denmark
https://orcid.org/0000-0002-4906-6022View further author information
https://orcid.org/0000-0002-4906-6022View further author information, Anne Danøa Incentive Denmark Aps, Holte, Denmarkhttps://orcid.org/0000-0003-2051-5186View further author information
https://orcid.org/0000-0003-2051-5186View further author information, Oskar Eklundb Gilead Sciences Sweden AB, Solna, Swedenhttps://orcid.org/0009-0000-8704-5022View further author information
https://orcid.org/0009-0000-8704-5022View further author information, Sachin Vadgamac Kite Pharma, a Gilead Company, Uxbridge, UKhttps://orcid.org/0000-0002-9138-8471View further author information
https://orcid.org/0000-0002-9138-8471View further author information, Viktor Hedlof Kanjeb Gilead Sciences Sweden AB, Solna, Swedenhttps://orcid.org/0009-0002-3384-1140View further author information
https://orcid.org/0009-0002-3384-1140View further author information & Emma Munka Incentive Denmark Aps, Holte, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0002-8295-2923View further author information
https://orcid.org/0000-0002-8295-2923View further author information